Rhythm Pharmaceuticals' Imcivree Could Reach $2 Billion in Worldwide Sales by 2030, RBC Says

MT newswire2026/11/04 15:59

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

11:59 AM EST, 11/04/2026 (MT Newswires) -- Rhythm Pharmaceuticals' (RYTM) Hypothalamic Obesity drug Imcivree could reach over $2 billion in worldwide sales by 2030, RBC Capital Markets analysts said in a Tuesday note. Analysts said that the company is "pleased" with its Hypothalamic Obesity launch in the United States and does not see cadence slowing into Q4. Outside the United States, the company views Japan as a larger opportunity than countries like Germany or France due to more attractive pricing and the potential for more rapid diagnosis. Analysts said that the company's progress in its Prader-Willi Syndrome trial and next-gen agents could drive future upside. RBC reiterated an Outperform, Speculative Risk rating and a $159 price target on the stock. Shares of the company were up 5.3% in Wednesday trading. Price: 93.21, Change: +6.77, Percent Change: +7.83

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.

华尔街见闻•2026/11/09 10:26